| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
63,440,000 |
| Market
Cap: |
194.13(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.72 - $4.04 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 5.8 |
| Insider 6 Months : 5.8 |
| Insider 3/6 Months : 12 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ovid Therapeutics is a biopharmaceutical company focused on developing medicines for patients and families living with epilepsies, seizure-related disorders and neurological disorders. Co. has two drug candidates (gaboxadol and soticlestat) from pre-clinical proof of concept and either through trials or to the initiation of trials, whether by Co. or its collaborators. Co.'s drug candidates include: Soticlestat, which is an inhibitor of cholesterol 24 hydroxylase that modulates the excitatory signals involved in epilepsy, and thereby suppress seizures; and OV329, which is being developed for the treatment of seizures associated with Tuberous Sclerosis Complex and Infantile Spasms.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
18,248 |
18,248 |
18,248 |
18,248 |
| Total Buy Value |
$50,364 |
$50,364 |
$50,364 |
$50,364 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
17,344 |
| Total Sell Value |
$0 |
$0 |
$0 |
$37,290 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Levin Jeremy M |
CEO |
• • – |
2024-03-18 |
4 |
B |
$2.76 |
$50,364 |
D/D |
18,248 |
3,616,715 |
2.81 |
12% |
|
| Perone Thomas Michael |
General Counsel, Secretary |
• – – |
2024-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
28,125 |
28,125 |
|
- |
|
| Rona Jeffrey A |
CBFO |
• – – |
2024-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
28,125 |
28,125 |
|
- |
|
| Tardio Jason |
Chief Operating Officer |
• – – |
2024-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
28,125 |
28,125 |
|
- |
|
| Levin Jeremy M |
CEO |
• • – |
2023-12-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,146,550 |
3,598,467 |
|
- |
|
| Tardio Jason |
Chief Operating Officer |
• – – |
2022-09-12 |
4 |
S |
$2.15 |
$37,290 |
D/D |
(17,344) |
0 |
|
-11% |
|
| Takeda Pharmaceuticals U.s.a., Inc. |
10% Owner |
– – • |
2022-07-01 |
4 |
A |
$0.00 |
$0 |
I/I |
5,750,000 |
5,750,000 |
|
- |
|
| Takeda Pharmaceuticals U.s.a., Inc. |
10% Owner |
– – • |
2022-07-01 |
4 |
D |
$0.00 |
$0 |
I/I |
(5,750,000) |
0 |
|
- |
|
| Rakhit Amit |
President and CMO |
• – – |
2021-07-14 |
4 |
S |
$3.71 |
$126,203 |
D/D |
(34,017) |
726,823 |
|
8% |
|
| Rakhit Amit |
President and CMO |
• – – |
2021-07-14 |
4 |
OE |
$1.89 |
$64,292 |
D/D |
34,017 |
760,840 |
|
- |
|
| Levin Jeremy M |
CEO |
• • • |
2020-08-28 |
4 |
B |
$5.84 |
$49,570 |
D/D |
8,488 |
5,792,530 |
3.23 |
-58% |
|
| Millennium Pharmaceuticals Inc |
10% Owner |
– – • |
2019-10-08 |
4 |
B |
$2.50 |
$5,000,000 |
I/I |
2,000,000 |
5,750,000 |
1.5 |
- |
|
| Levin Jeremy M |
CEO |
• • • |
2019-10-08 |
4 |
B |
$2.50 |
$150,000 |
D/D |
60,000 |
4,736,529 |
3.23 |
- |
|
| Levin Jeremy M |
CEO |
• • – |
2019-09-20 |
4/A |
GD |
$0.00 |
$0 |
I/I |
465,116 |
0 |
|
- |
|
| Bernstein Karen |
Director |
– • – |
2019-02-26 |
4 |
B |
$2.02 |
$20,210 |
D/D |
10,000 |
20,000 |
2.39 |
- |
|
| Millennium Pharmaceuticals Inc |
10% Owner |
– – • |
2019-02-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,750,000 |
|
- |
|
| Millennium Pharmaceuticals Inc |
10% Owner |
– – • |
2019-02-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,781,996 |
|
- |
|
| Levin Jeremy M |
CEO |
• • • |
2019-02-22 |
4 |
B |
$2.00 |
$150,000 |
D/D |
75,000 |
4,676,529 |
3.23 |
- |
|
| Williams Douglas E |
Director |
– • – |
2018-08-14 |
4 |
B |
$6.49 |
$32,442 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| Bernstein Karen |
Director |
– • – |
2018-08-14 |
4 |
B |
$6.23 |
$62,300 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Levin Jeremy M |
CEO |
• • • |
2017-08-25 |
4 |
B |
$7.15 |
$109,638 |
D/D |
15,334 |
4,601,529 |
3.23 |
- |
|
| Levin Jeremy M |
CEO |
• • • |
2017-05-10 |
4 |
A |
$0.00 |
$0 |
I/I |
35,461 |
35,461 |
|
- |
|
| Levin Jeremy M |
CEO |
• • • |
2017-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
400,150 |
4,586,195 |
|
- |
|
| During Matthew |
President and CSO |
• • • |
2017-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
28,245 |
4,307,314 |
|
- |
|
| During Matthew |
President and CSOOfficer |
• • • |
2017-05-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
372,092 |
|
- |
|
28 Records found
|
|
Page 1 of 2 |
|
|
0.01 (0.33%) 
